Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment

According to a story from globenewswire.com, the genetic medicines company Homology Medicines, Inc. has recently announced that it has opened enrollment for its phase 1/2 clinical trial. This clinical trial…

Continue Reading Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

A recent study published in PLOS Biology has shown a promising new vulnerability within human viruses which could lead to the development of a new antiviral drug. This study was…

Continue Reading Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU

Transfusion-Dependent β-Thalassemia (TDT) Transfusion-dependent β-thalassemia (TDT) is a rare disease that is caused by a mutated β-globin gene. This mutation causes the amount of hemoglobin in the body to be…

Continue Reading ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU
Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
stevepb / Pixabay

Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

According to a press release from Danish biopharmaceutical company Orphazyme, the Company intents to proceed with a marketing authorisation application (MAA) for its experimental Niemann-Pick disease type C treatment arimoclomol.…

Continue Reading Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

Hereditary Hemochromatosis Hereditary hemochromatosis (HH) is a rare disease caused by hepcidin deficiency or hepcidin insensitivity. Hepcidin naturally regulates iron absorption/distribution in the body. Without hepcidin, HH patients suffer from…

Continue Reading Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers

  The FDA’s “untitled letter” to R3 Stem Cell (R3), based in Scottsdale Arizona, cautioned R3 that the product they are marketing is considered a drug. It must, therefore, be…

Continue Reading The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers
Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe
Capri23auto / Pixabay

Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

According to a publication from BNN Bloomberg, regulatory authorities in the European Commission recently granted conditional marketing authorization (CMA) to Zynteglo. Zynteglo is a gene therapy designed to treat beta…

Continue Reading Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial

Friedreich's Ataxia Friedreich's ataxia (FRDA) is a rare disease which is caused by a frataxin deficiency. This deficiency results in the degeneration of nerves within the spinal cord. This nerve…

Continue Reading Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial

“Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research

Systemic Sclerosis Systemic Sclerosis (Systemic Scleroderma) is a rare disease which results in the hardening of the connective tissues in the body as well as the skin. It can affect…

Continue Reading “Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research

The PoppyPocket Helps Patients Wear Their Infusion Pumps More Comfortably, Safely, and Confidently

The PoppyPocket The PoppyPocket is a wearable pocket, created to make wearing infusion pumps and well as other medical devices easier, safer, and more comfortable. It comes with two pockets,…

Continue Reading The PoppyPocket Helps Patients Wear Their Infusion Pumps More Comfortably, Safely, and Confidently

Experimental Treatment for Spinocerebellar Ataxia Earns Orphan Drug Designation from the FDA

According to a story from Business Wire, the drug developer Cadent Therapeutics recently announced that its investigational drug CAD-1883 has been awarded Orphan Drug Designation from the US Food and…

Continue Reading Experimental Treatment for Spinocerebellar Ataxia Earns Orphan Drug Designation from the FDA

NuEyes: Using Virtual Reality to Improve Vision for Achromatopsia, Congenital Nystagmus & Macular Degeneration Patients

An Idea Sometimes life leads us down unexpected paths. Mark Greget founded a medical device distribution company. That was his plan. But after interacting with patients through his work, he…

Continue Reading NuEyes: Using Virtual Reality to Improve Vision for Achromatopsia, Congenital Nystagmus & Macular Degeneration Patients

Chiari Malformation Patient Hasn’t Let 6 Brain Surgeries or a Stroke Stop Her from Continuing Medical School

The Beginning of the Journey Claudia Martinez is a medical student at UTHealth McGovern Medical School. Her dream is, and always has been, to be a doctor. But an unexpected…

Continue Reading Chiari Malformation Patient Hasn’t Let 6 Brain Surgeries or a Stroke Stop Her from Continuing Medical School
First Treatment in China for Morquio A Syndrome Earns Approval
Free-Photos / Pixabay

First Treatment in China for Morquio A Syndrome Earns Approval

According to a story from Market Screener, the biotechnology company BioMarin Pharmaceutical Inc. recently announced that the Chinese government has approved the company's drug elosulfase alfa (marketed at Vimizim) as…

Continue Reading First Treatment in China for Morquio A Syndrome Earns Approval